Mardi Dier sold $854k of MDGL
EVP and CFO at MADRIGAL PHARMACEUTICALS, INC.. 1,982 shares at an average of $430.87, traded Mar 6, 2026, filed Mar 6, 2026.
Score components
- +22RoleCFO
- +23Trade size$854k at market
- +5Share of holdings soldSold 14% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +26.4%, 3m +12.5%, 6m +25.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-015775, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | AGrant or award Common Stock10b5-1 | +5,215 | $0.00 | $0 | 14,472 | Mar 6, 2026 |
| Mar 6, 2026 | SOpen-market sale Common Stock10b5-1 | -646 | $431.94 | $279k | 13,826 | Mar 6, 2026 |
| Mar 6, 2026 | SOpen-market sale Common Stock10b5-1 | -40 | $425.08 | $17k | 13,786 | Mar 6, 2026 |
| Mar 6, 2026 | SOpen-market sale Common Stock10b5-1 | -420 | $426.86 | $179k | 13,366 | Mar 6, 2026 |
| Mar 6, 2026 | SOpen-market sale Common Stock10b5-1 | -80 | $427.85 | $34k | 13,286 | Mar 6, 2026 |
| Mar 6, 2026 | SOpen-market sale Common Stock10b5-1 | -160 | $429.00 | $69k | 13,126 | Mar 6, 2026 |
| Mar 6, 2026 | SOpen-market sale Common Stock10b5-1 | -40 | $429.58 | $17k | 13,086 | Mar 6, 2026 |
| Mar 6, 2026 | SOpen-market sale Common Stock10b5-1 | -120 | $430.90 | $52k | 12,966 | Mar 6, 2026 |
| Mar 6, 2026 | SOpen-market sale Common Stock10b5-1 | -116 | $432.56 | $50k | 12,850 | Mar 6, 2026 |
| Mar 6, 2026 | SOpen-market sale Common Stock10b5-1 | -160 | $434.20 | $69k | 12,690 | Mar 6, 2026 |
| Mar 6, 2026 | SOpen-market sale Common Stock10b5-1 | -80 | $435.32 | $35k | 12,610 | Mar 6, 2026 |
| Mar 6, 2026 | SOpen-market sale Common Stock10b5-1 | -80 | $436.69 | $35k | 12,530 | Mar 6, 2026 |
| Mar 6, 2026 | SOpen-market sale Common Stock10b5-1 | -40 | $437.65 | $18k | 12,490 | Mar 6, 2026 |
| Mar 4, 2026 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +6,519 | $0.00 | $0 | 6,519 | Mar 6, 2026 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 30Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $342k 664 shares | -5% | |
| 35Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $1.4M 2,500 shares | -1% | |
| 21Weak | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $517k 1,042 shares | -9% | |
| 33Weak | MADRIGAL PHARMACEUTICALS, INC. | Richard S Levy director | $2.9M 5,682 shares | -21% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $435k 844 shares | -7% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $181k 419 shares | -3% | |
| 41Moderate | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $155k 360 shares | -3% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub Pres., R&D, and CMO | $212k 491 shares | -0% | |
| 61Notable | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $718k 1,663 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.